课题基金 / 基金详情

LONG TERM SAFETY & EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS

LONG TERM SAFETY & EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS
长期安全
批准号：
6264625
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264625
关键词：
acromegaly clinical research drug adverse effect drug screening /evaluation endocrine disorder chemotherapy hormone therapy human subject human therapy evaluation insulinlike growth factor peptide hormone analog somatostatin somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
这项开放标签试验的目的是通过GH和IGF-1水平的标准化来指导剂量，以研究兰瑞肽(IPSTYL)治疗肢端肥大症的长期安全性和有效性。受试者必须事先参加过IPSTYL的试验。第二个目标是研究IPSTYL在肿瘤反应、控制/减少肢端肥大症症状的能力、不良事件以及IGF-1水平正常化方面的有效性和安全性。
英文摘要
The objectives of this open-label trial are to investigate the long-term safety and efficacy of lanreotide (IPSTYL) in the treatment of acromegaly by using normalization of GH and IGF-1 levels to guide dosing. Subjects must have been enrolled in a prior trial of IPSTYL. Secondary objectives are to investigate the efficacy and safety of IPSTYL in terms of tumor response, ability to control/reduce symptoms of acromegaly, adverse events and normalization of IGF-1 levels in a group of patients who have near normal levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金